Eculizumab interruption in atypical hemolytic uremic syndrome due to shortage: analysis of a Brazilian cohort
Sign Up to like & getrecommendations! Published in 2021 at "Journal of Nephrology"
DOI: 10.1007/s40620-020-00920-z
Abstract: Background The risk of eculizumab therapy discontinuation in patients with atypical hemolytic uremic syndrome (aHUS) is unclear. The main objective of this study was to analyze the risk of aHUS relapse after eculizumab interruption due to… read more here.
Keywords: nephrology; atypical hemolytic; relapse; shortage ... See more keywords